Todays Report: Today: 59,650 Shares of Valeant Pharmaceuticals International Inc. (VRX) are sold by TD Asset Management Inc.

Today: 59,650 Shares of Valeant Pharmaceuticals International Inc. (VRX) are sold by TD Asset Management Inc.

TD Asset Management Inc. lowered its stake in shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) (TSE:VRX) by 3.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,478,702 shares of the specialty pharmaceutical company’s stock after selling 59,650 shares during the period. TD Asset Management Inc.’s holdings in Valeant Pharmaceuticals International were worth $36,218,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its stake in Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock valued at $129,000 after buying an additional 402 shares during the last quarter. Boothbay Fund Management LLC raised its stake in Valeant Pharmaceuticals International by 275.4% in the first quarter. Boothbay Fund Management LLC now owns 7,632 shares of the specialty pharmaceutical company’s stock valued at $201,000 after buying an additional 5,599 shares during the last quarter. Cacti Asset Management LLC raised its stake in Valeant Pharmaceuticals International by 68.0% in the second quarter. Cacti Asset Management LLC now owns 8,400 shares of the specialty pharmaceutical company’s stock valued at $169,000 after buying an additional 3,400 shares during the last quarter. AGF Investments Inc. raised its stake in Valeant Pharmaceuticals International by 121.9% in the second quarter. AGF Investments Inc. now owns 8,842 shares of the specialty pharmaceutical company’s stock valued at $178,000 after buying an additional 4,857 shares during the last quarter. Finally, Carl Domino Inc purchased a new stake in Valeant Pharmaceuticals International during the third quarter valued at approximately $225,000. 64.97% of the stock is owned by institutional investors and hedge funds.

Shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) traded up 3.35% during mid-day trading on Monday, hitting $17.57. The company had a trading volume of 8,456,324 shares. The company’s market cap is $6.11 billion. The firm has a 50-day moving average of $20.02 and a 200-day moving average of $24.13. Valeant Pharmaceuticals International Inc. has a 12 month low of $13.77 and a 12 month high of $119.87.

Valeant Pharmaceuticals International (NYSE:VRX) last announced its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.78 by $0.23. Valeant Pharmaceuticals International had a positive return on equity of 43.81% and a negative net margin of 22.17%. The business had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.49 billion. During the same period in the prior year, the company earned $2.74 EPS. The company’s revenue was down 11.0% on a year-over-year basis. On average, analysts expect that Valeant Pharmaceuticals International Inc. will post $5.44 EPS for the current year.

Several analysts have commented on the stock. Wells Fargo & Co. reissued a “sell” rating and set a $19.50 price target on shares of Valeant Pharmaceuticals International in a research report on Sunday, September 18th. Deutsche Bank AG set a $24.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Sunday, November 20th. Canaccord Genuity set a $17.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Saturday, November 19th. Scotiabank reaffirmed a “sector perform” rating and issued a $17.00 price objective (down from $32.00) on shares of Valeant Pharmaceuticals International in a research report on Thursday, November 10th. Finally, Mizuho reaffirmed a “neutral” rating and issued a $25.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Tuesday, November 1st. Four equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and a consensus target price of $39.63.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Related posts

Leave a Comment